A similar therapeutic approach modulating the granulocyte-macrophage colony-stimulating factor (GM-CSF) instead of targeting its receptor is currently in phase II clinical trial for AD (NCT01409915), which has been recently completed although no results have been published yet. The gene discussed is CSF2; the disease is Alzheimer disease.